All In Biotech

BLA 205692 · Eli Lilly and CO

Basaglar

Insulin Glargine · Subcutaneous · Insulin Analog

Last checked: Nov 20, 2026Latest source record: Jul 20, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Dec 16, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

679

239 Phase 3, 12 recruiting

FAERS reports

45,246

26,158 serious, 3,004 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 16, 2026.

BASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for treating diabetic ketoacidosis. ( 1 ) Limitations of Use BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

Mechanism: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 16, 2015 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLetter
1 products under this application
  • BASAGLAR · INSULIN GLARGINE 300 UNITS/3ML (100 UNITS/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Glargine" as an intervention, any sponsor and status, largest first.

All 679 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased7,220
  • incorrect dose administered2,585
  • drug ineffective2,134
  • visual impairment2,008
  • hypoglycaemia1,944
  • blood glucose decreased1,684
  • nausea1,591
  • accidental underdose1,544
  • diarrhoea1,438
  • injection site pain1,423
  • fatigue1,345
  • inappropriate schedule of product administration1,306

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200499
2005108
200689
2007111
2008169
2009191
2010299
2011360
2012264
2013403
2014423
2015619
2016740
20172,296
20184,877
20195,649
20204,766
20214,528
20224,659
20233,922
20244,035
20253,981
20262,657

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 987 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.